The publication of this article was supported by Bristol Myers Squibb.
The panel at ESTS 2024 discussed the evolving landscape of lung cancer treatment. Exploring the potential benefits of neoadjuvant chemo-immunotherapy as a preferred first-line strategy for stage II and III resectable non-small cell lung cancer (NSCLC).
Key topics covered include:
- Neoadjuvant Therapy: Learn why this approach may offer advantages over traditional surgical and adjuvant treatment.
- Pathological Response: Understand the significance of pathological complete response (pCR) and other metrics in predicting patient outcomes.
- Real-World Implementation: Explore the challenges and opportunities in integrating new therapies into clinical practice.
- Case Studies: Gain valuable insights from real-world case scenarios.
Faculty:
Jonathan Spicer1
Ernest Nadal2
1. McGill University; Montreal General Hospital, Montreal, Canada
2. Catalan Institute of Oncology, Barcelona, Spain
